Search Results
Results found for "pain research"
- Dr. GPCR Virtual Cafe with Matthew Eddy - New date!
Don't miss the chance to listen to his latest research on the field.
- Therapeutic validation of an orphan G protein‐coupled receptor
Some studies have also reported GPR84 involvement in pain, atherosclerosis, and even metabolic disorders
- 📰 GPCR Weekly News, December 18 to 31, 2023
mediated neuroprotective mechanism through autophagy-mediated NLRP3 degradation Methods & Updates in GPCR Research Principal Investigator, In Vitro Biology NEW Associate Scientist Postdoctoral Scholar - O’Neill Lab Junior Research Scientist Postdoctoral Fellow Post-Doc Research Associate Assistant/Associate Professor Explore Dr.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
This concept is gaining significant attention in drug discovery, especially in the context of G protein-coupled Research by Prof.
- Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein kinase C...
Our PKC KO cell lines expand the repertoire of KO HEK293A cell lines available to research GPCR pharmacology isozymes generally lack specificity and/or potency, we present the PKC KO cell lines as more specific research
- Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
understanding of psychedelic pharmacology is derived from rodent models, but most of this preclinical research mice, and support the importance of studying sex as a biological variable in preclinical psychedelic research
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
Research using techniques like bioluminescence resonance energy transfer (BRET) and fluorescence resonance In summary, dimerization in class B1 GPCRs is an emerging area of research that has far-reaching implications
- 📰 GPCR Weekly News
impairs growth of patient-derived xenografts of colorectal carcinoma in mice Methods & Updates in GPCR Research Interactions in the Serotonin 1A Receptor Microenvironment Industry News Addex and Indivior Extend Research
- Adhesion GPCR Consortium Newsletter - May 2024
Investigación y de Estudios Avanzados del IPN (Cinvestav) How did you become involved in adhesion GPCR research What challenges will researchers overcome in the next 10 years? AB: The next workshop will likely bring together some of the hottest adhesion GPCR research going on
- A cryptic mode of GPCR regulation revealed
October 2022 "Over three decades of research have provided thorough insights into G protein-coupled receptor
- 📰 GPCR Weekly News, October 23 to 29, 2023
Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies Methods & Updates in GPCR Research Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research
- Novo Nordisk moves to strengthen obesity efforts
Under the joint research plan, the Danish giant will work with EraCal to identify novel drug targets
- Pharmacology at Your Fingertips: Terry’s Corner Launches
GPCR partner Celtarys Research has validated a TR-FRET assay for cannabinoid receptor ligands using their
- 📰 GPCR Weekly News, March 13 to 19, 2023
A small molecule ligand for the novel pain target, GPR171, produces minimal reward in mice.
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead
- Cell Surface Calcium-Sensing Receptor Heterodimers: Mutant Gene Dosage Affects Ca 2+ Sensing but...
Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)."
- Tectonic Therapeutic Strengthens Leadership Team
therapies (G-Protein Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research
- Function and structure of bradykinin receptor 2 for drug discovery
review, we summarize the structure and function of B2R in relation to drug discovery and discuss future research
- Molecular insights into psychedelic drug action
desire for additional approaches to mental health care, incremental progress in basic and clinical research
- Molecular targets of psychedelic-induced plasticity
August 2022 "Psychedelic research across different disciplines and biological levels is growing at a
- 4GPCRnet, September 26-29, 2022. Leipzig, Germany
Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded
- Neurotransmitters: Potential Targets in Glioblastoma
neurotransmitter receptors have shown great potential for inhibiting GBM growth and development, requiring further research
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous Nobel laureate Robert Lefkowitz, M.D., has 50 years of experience with the target and analogizes the search
- Chemokine receptor-targeted drug discovery: progress and challenges
inappropriate target selection and insufficient dosing of chemokine receptor antagonists in vivo might be the main the notion that redundancy is not a feature of the chemokine system (Nedjai et al. 2012), but more research
- 📰 GPCR Weekly News, June 19 to 25, 2023
Methods & Updates in GPCR Research A coiled-coil-based design strategy for the thermostabilization of the Gliovascular Unit of Glioblastoma Associate Director / Director, Clinical Operations Postdoctoral Research
- Michel Bouvier appointed Knight of the Ordre national du Québec
Michel Bouvier, Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology Research
- Community guidelines for GPCR ligand bias: IUPHAR review 32
requires that we now characterize physiological signalling not just by receptors but by ligand-receptor pairs The guidelines will aid consistency and clarity, as the basic receptor research and drug discovery communities
- GPCR Therapeutics Expands Scientific Advisory Board
with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs Jon Wigginton will provide scientific expertise to support the company’s research and clinical development
- Domain Therapeutics Raises $42m Series A Financing
STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research
- Dr. Adriano Marchese - Dr. GPCR Podcast
Learn about his remarkable career and research in #GPCR signaling and trafficking.





